130 results about "Radiosensitivity" patented technology

A sulfonic acid onium salt represented by the following formula (1) can be used as a superior radiosensitive acid generator for resist compositions. It is possible to form a good pattern by using a resist composition containing this sulfonic acid onium salt.In formula (1), R1 represents a monovalent organic group, and Q+ represents a sulfonium cation or iodonium cation.

The invention provides a test device for testing the radiation sensitivity of an electric field and a test method thereof. The test device comprises a main control computer, a PCI (Personal Communication Interface)-GPIB (General Purpose Interface Bus) control card, a signal generator, a switch array, a power amplifier A, a power amplifier B, a coupler A, a coupler B, a power meter, an antenna A,an antenna B, a field intensity probe and a field intensity monitor. The test device solves the problem of serious attenuation of radio-frequency signals of a 10kHZ-40GHz frequency range signal generator during remote transmission based on different transmission characteristics of radio frequency signals at high and low frequency bands. When equipment under test abnormally works during the automatic control test process, the test method can be immediately switched to the radiation sensitivity manual test of the electric field; and after the normality is restored, the manual test is switched back to the automatic test, so as to continuously test till the whole test process is finished. The test device is convenient and flexible to operate and has high safety and reliability.

Provided is a pattern forming method that is excellent in roughness performance such as line width roughness and exposure latitude, and an actinic-ray-sensitive or radiation-sensitive resin composition and a resist film used for the pattern forming method.The pattern forming method includes (1) forming a film using an actinic-ray-sensitive or radiation-sensitive resin composition containing a resin that includes 65 mol % or more of a repeating unit having a group which generates a polar group by being degraded by the action of an acid based on all repeating units in the resin and at least one kind of repeating unit represented by the following General Formula (I) or (II), (2) exposing the film, and (3) developing the exposed film using a developer that contains an organic solvent.

Inhibitors of KIAA0175 are provided that reduce the expression or biological activities of KIAA0175, p53 and / or p21 in a mammalian cell. KIAA0175 inhibitors include anti-sense molecules, ribozymes, antibodies and antibody fragments, proteins and polypeptides as well as small molecules. KIAA0175 inhibitors find use in compositions and methods for decreasing KIAA0175, p53 and / or p21 gene expression as well as methods for increasing the chemo and / or radiosensitivity of mammalian cells, including tumor cells, methods for decreasing the side effects of cancer therapy and methods for treating neoplastic diseases.

Compositions, kits and methods for treating cancer in a subject in need thereof are disclosed involving one or more genes the suppression of which renders the cancer chemosensitive and / or radiosensitive.

The invention discloses application of a miRNA (Micro-Ribonucleic Acid) expression profile in predicting the sensibilities of lung cancer patients to the radiotherapy. A preparation method for the invention comprises the following steps of: selecting lung cancer patients who are clinically unusually sensitive and highly tolerant to the radiotherapy, drawing 5ml of peripheral blood, and extracting total RNA by using a TRIZOL kit (Invitrogen); then hybridizing by using a MicroRNA expression profile chip; carrying out data processing, and analyzing the difference of MicroRNA expression profiles of radiotherapy sensitive and non-sensitive patients by using a cluster analysis method; and finally, checking a result by using a Real-time PCR (Polymerase Chain Reaction) method. The inventor finds that an expression profile consisting of 12 miRNA can regulate and control the expression of genes relevant to tumor radiosensitivity and be used for predicting the sensitivity of the lung cancer patients to the radiotherapy and providing an experimental foundation of an early period for the individualized radiotherapy of lung cancer.

The invention provides a radiosensitivity test method used for protecting a power magnifier. The method figures out the limit of the minimal sensitivity through power and also the minimal input power provided by a signal source to guarantee that a standing wave ratio is stable in a wider band limit when the power value which is greater than the minimal input power is input so as to guarantee the effectiveness of the standing wave ratio protecting the power magnifier; the maximal allowable reflection power is adopted to define the maximal input power of the signal source and a standard field intensity value is adopted, so as to define the field intensity stressed to EUT and guarantee that the power magnifier cannot be damaged by an excessive reflection power in the band limit. With the invention, a smooth process of the radiosensitivity test and the safety of the power magnifier can be effectively guaranteed.

Inositol-tripyrophosphate is an allosteric effector of hemoglobin due to its ability to cross the plasma membrane of red blood cells and deliver oxygen to solid tumors, by lowering the oxygen affinity of the hemoglobin of red blood cells. The present invention is directed to the use of inositol-tripyrophosphate to reduce hemoglobin's affinity for oxygen in circulating red blood cells. The present invention is further directed to the use of inositol-tripyrophosphate to inhibit angiogenesis and enhance radiation sensitivity of hypoxic tumors. The present invention is further directed to the use of inositol-tripyrophosphate to enhance PO2 in hypoxic tumors.

This invention is a model that simulates the complexity of biological signaling in a cell in response to radiation therapy. Using gene expression profiles and radiation survival assays in an algorithm, a systems model was generated of the radiosensitivity network. The network consists of ten highly interconnected genetic hubs with significant signal redundancy. The model was validated with in vitro tests perturbing network components, correctly predicting radiation sensitivity 2 / 3 times. The model's clinical relevance was shown by linking clinical radiosensitivity targets to the model network. Clinical applications were confirmed by testing model predictions against clinical response to preoperative radiochemotherapy in patients with rectal or esophageal cancer.

An actinic ray-sensitive or radiation-sensitive resin composition includes (A) a resin having at least two of repeating units represented by general formula (1) below and exhibiting increased solubility in an alkali developer when acted on by an acid, and (B) a compound that generates an acid when exposed to actinic rays or radiation.In the formula, each of R, A, R0, Z, L and n represents the same as defined in the claims and in the specification.

Inhibitors of KIAA0175 are provided that reduce the expression or biological activities of KIAA0175, p53 and / or p21 in a mammalian cell. KIAA0175 inhibitors include anti-sense molecules, ribozymes, antibodies and antibody fragments, proteins and polypeptides as well as small molecules. KIAA0175 inhibitors find use in compositions and methods for decreasing KIAA0175, p53 and / or p21 gene expression as well as methods for increasing the chemo and / or radiosensitivity of mammalian cells, including tumor cells, methods for decreasing the side effects of cancer therapy and methods for treating neoplastic diseases.

An actinic ray-sensitive or radiation-sensitive resin composition comprising (P) a resin having a repeating unit represented by the following formula (1), a resist film using the composition, and a pattern forming method.

A pattern forming method is disclosed which comprises providing a to-be-processed film on a substrate, providing a resist film on the to-be-processed film, patterning the resist film, providing a film of a radiosensitive compound on the to-be-processed film such that the patterned resist film is covered with the film of the radiosensitive compound, subjecting the film of the radiosensitive compound to irradiation and a development process, thus exposing an upper surface of the resist film and patterning the film of the radiosensitive compound, and removing the resist film and processing the to-be-processed film, using the patterned film of the radiosensitive compound as a mask.

This invention is a model that simulates the complexity of biological signaling in a cell in response to radiation therapy. Using gene expression profiles and radiation survival assays in an algorithm, a systems model was generated of the radiosensitivity network. The network consists of ten highly interconnected genetic hubs with significant signal redundancy. The model was validated with in vitro tests perturbing network components, correctly predicting radiation sensitivity 2 / 3 times. The model's clinical relevance was shown by linking clinical radiosensitivity targets to the model network. Clinical applications were confirmed by testing model predictions against clinical response to preoperative radiochemotherapy in patients with rectal or esophageal cancer.

An object of the invention is to provide a liquid crystal alignment agent which has excellent radiosensitivity and shows good liquid crystal alignment properties in the low-irradiation photo alignment method. A liquid crystal alignment film forming method using the liquid crystal alignment agent and a liquid crystal alignment film are provided. A liquid crystal display element which contains the liquid crystal alignment film and has excellent performances, such as electrical properties, in addition to the liquid crystal alignment properties, is provided. Further, a compound which serves as material of the liquid crystal alignment agent is provided. The liquid crystal alignment agent provided by the invention comprises an [A] polymer which has a structural unit (I) containing a radical represented by the following formula (1) or a radical represented by the following formula (2). Besides, the [A] polymer is preferably polyester or polythioester.

The invention relates to a device for selecting stem cells with a serum free medium for amplification of stem cells. The invention also relates to a method of treating or preventing diseases caused by cancer-related stem cells. The invention further provides a method of enhancing radiosensitivity of cancer-related stem cells comprising radiotherapy with resveratrol, and the cancer-related stem cell has stronger drug resistance. The present invention further provides that resveratrol promotes differentiation and inhibits teratoma / tumor formation in induced pluripotent stem cells (iPS) and embryonic stem cells

Disclosed is a liquid crystal aligning agent containing a radiation-sensitive polyorganosiloxane which is obtained by reacting a cinnamic acid derivative having at least one group selected from the group consisting of a carboxyl group, a hydroxyl group, -SH, -NCO, -NHR (wherein R represents a hydrogen atom or an alkyl group having 1-6 carbon atoms), -CH=CH2 and -SO2Cl with a polyorganosiloxane having an oxethane ring.

The invention discloses a radiosensitivity testing method. The method comprises the steps that S1, three-dimensional simulation model data of a tested object and near-field radiation field intensity distribution data of a radiating antenna are acquired; S2, according to the three-dimensional simulation model data of the tested object and the near-field radiation field intensity distribution data of the radiating antenna, different frequency electromagnetic wave incident field intensity distribution data of the tested object in different testing distances at different positions is obtained; andS3, according to the electromagnetic wave incident field intensity distribution data, 3dB field intensity coverage data and field intensity uniformity data of the radiating antenna are acquired, a sufficient coverage test is performed, testing position data is obtained, and radiosensitivity testing is completed. Through the method, intensity distribution of incident field intensity on surfaces ofobjects in different shapes can be given according to different testing distances and different frequencies, and the field intensity uniformity in a test radiating area can be assessed to guide electromagnetic protection research and development of the tested object.

The invention discloses a radiotherapy-targeted sensitizer, comprising the following seven miRNAs: an hsa-miR-138-2-3p stimulant, an hsa-miR-208b-3p stimulant, an hsa-miR-197-3p inhibitor, an hsa-miR-20b-3p inhibitor, an hsa-let-7a-5p inhibitor, an hsa-miR-16-1-3p inhibitor and an hsa-miR-21-5p inhibitor. The invention provides a novel radiotherapy-targeted sensitizer, which is capable of enhancing the radiosensitivity and is small in toxic and side effects, is especially applied to laryngeal cancer patients at various stages, and has an important application prospect. The novel radiotherapy-targeted sensitizer disclosed by the invention is expected to play a great role in improvement of the radiosensitivity and further increase of the curative effect, and good economic and social benefits are generated.

The invention discloses a method of detecting radiosensitivity of lung cancer cells on x ray, a chip and an application. The method comprises the following steps: selecting lung cancer cells which are abnormally sensitive to and tolerant to radiotherapy; detecting expression difference of micro RNA in two groups of cells by using a micro RNA expression profile chip; verifying the chip result by means of a Real-Time PCR technology; and finally, screening 11 microRNAs which has remarkable difference. The method disclosed by the invention can be used for predicting sensitivity of the lung cancer cells on radiotherapy.

The invention discloses use of a transforming growth factor (TGF)-beta1 inhibitor in lung cancer treatment. The TGF-beta1 inhibitor inhibits a TGF-beta1 channel to increase the radiosensitivity of lung cancer cells. Through the manner, according to the use of the TGF-beta1 inhibitor in lung cancer treatment, the sensitivity enhancement effect of the TGF-beta1 inhibitor on the lung cancer cells is caused by inhibition on non-homologous end joining repair of deoxyribonucleic acid (DNA) double-strand break, change of cycle distribution of the lung cancer cells after irradiation, and obvious reduction of tumor growth by the TGF-beta1 inhibitor combined with X-ray treatment of 5Gy. The DNA repair capacity can be reduced by inhibition on the TGF-beta1 channel of tumor cells before irradiation, the cell cycle distribution is changed, the cell cloning ability is reduced, the tumor growth is delayed, and effective auxiliary means are provided by inhibiting the TGF-beta1 channel as radiotherapy of a patient with a lung cancer.

The invention discloses application of the combination of gamma ray and phTERTp-HRP / IA in medicines for killing larynx cancer cells, and in particular relates to the enhancement of the gamma ray in promoter activity of hTERT gene and the synergetic effect of the combination of the gamma ray and the phTERTp-HRP / IA for killing the human larynx cancer cells. The invention studies levels of different radiation sensitivity cancer cells in cells and animals and detects the promoter activity and enzymatic activity, volume, weight and tumor inhibiting rate of transplanted tumor, tumor tissue HE coloration and apoptosis of lower-reach gene expression products to evaluate the synergetic killing effect when the gamma ray treatment and the hTERT promoter regulating-controlling HRP / IAA system gene treatment are jointly used. The result shows that when the gamma ray treatment and the phTERTp-HRP / IAA treatment are jointly used, the human larynx cancer cells are obviously killed.

Provided are a synthetic peptide that increases the radiosensitivity of tumor cells and a pharmaceutical composition containing that synthetic peptide.The peptide provided by the present invention is a synthetic peptide having a radiosensitizing peptide sequence including the following amino acid sequence:CX2X3KX5X6X7X8C(wherein, X2 represents K or R, X3 represents S or A, X5 represents S or A, X6 represents R or G, X7 represents R or D and X8 represents S or P); or,a modified amino acid sequence in which one, two or three amino acid residues are substituted, deleted and / or added in that amino acid sequence. In addition, the pharmaceutical composition provided by the present invention is a composition used to increase the sensitivity of tumor cells to radiation in tumor radiation therapy, and contains the synthetic peptide described above.

The invention relates to a kit for detecting cancer radiosensitivity and application of the kit to curative effect prediction. According to the kit of the invention, the screening of molecular markersis completely based on whole-genome RNAi library screening which is a more practical and effective screening mode in international research level. Identification is carried out step by step in vitroand vivo based on a radiotherapy tolerance induction process; it is finally found that RFC4 is a gene highly correlated with radiotherapy tolerance of colorectal cancer; clinical retrospective analysis and in-vitro and in-vivo functional analysis are performed on the identified RFC4 gene, it is revealed that the high expression levels of the RFC4 gene can be positively correlated with tumor regression bad performance, and the RFC4 gene can be used to predict radiotherapy tolerance / sensitivity. Based on the above technical schemes of the invention, the kit used for predicting the efficacy of local advanced neoadjuvant radiotherapy is obtained, and is of great realistic significance for solving the problem of differences between individuals in clinical efficacies and the prediction blanks ofregression / prognosis effects, and better achieving accurate treatment.

The invention discloses an application of a long-chain non-coding RNA molecule SNHG18 in preparing a medicine for treating brain glioma, and in particular discloses an application in preparing a medicine for enhancing the radiosensitivity of a brain glioma cell. The application disclosed by the invention, from the new view of 1ncRNA, offers a new basis and a new idea for illuminating the malignant proliferation of malignant glioma and the molecular mechanism of radio-resistance, and provides a certain application value for the aspect of drug target. Therefore, the SNHG18 can be used for preparing a medicine for treating brain glioma, in particular for preparing a medicine for enhancing the radiosensitivity of a brain glioma cell.

The invention discloses a hydrophobic drug entrapped lipid-polymer with dual functions of targeting and radiosensitivity. The lipid-polymer comprises lipid molecules with a targeting function, a poly-nitroimidazole organic polymer with radiosensitivity and a hydrophobic anti-cancer drug, wherein the lipid molecules (DSPE-PEG-target) with the targeting function, soybean lecithin and DSPE-PEG are prepared from polypeptide and targeting molecules with the targeting function in the lipid molecules through chemical reactions, the hydrophobic poly-nitroimidazole organic polymer is prepared from functional groups, namely nitroimidazole, with the radiosensitivity under the action of polymerization, and the polymer is prepared from the targeting lipid molecules, the soybean lecithin, the poly-nitroimidazole organic polymer and the hydrophobic anti-cancer drug through hydrophilic / hydrophobic compounding. The radiosensitivity is improved, the synergetic treatment effects of radiotherapy and chemotherapy upon tumor are improved, and a toxic and side effect reduction function is achieved; and a synchronous treatment function of radiotherapy sensitizers and anti-cancer medicine molecules is achieved, and clinical practicability and practical treatment significances can be achieved.

The invention provides novel application of triterpene glucoside or pharmaceutically acceptable salts thereof. The triterpene glucoside or pharmaceutically acceptable salts thereof can be used for preparing tumor radiosensitizer. When the tumor radiosensitizer prepared from the triterpene glucoside and the pharmaceutically acceptable salts thereof which serve as active ingredients is used for tumor radiotherapy, radiosensitivity of tumors can be improved, and side effects of radiotherapy can also be reduced. In addition, the triterpene glucoside is non-toxic and does not hurt human normal cells, and therefore, the application of the triterpene glucoside or pharmaceutically acceptable salts thereof has a clinical application prospect.

The invention relates to the technical field of biomedicine engineering and provides application of a reagent for inhibiting or down-regulating expression of a GTSE1 gene in preparation of a tumor radiotherapy sensitization drug, particularly application in preparation of a lung cancer radiotherapy sensitization drug. Experiments prove that GTSE1 knockdown promotes DNA damage of exposure to lung cancer cells, increases the radiosensitivity of three lung censer cells significantly and increases the apoptosis rate of the three lung cancer cells after exposure significantly with the increase of an exposure dose, and the cell survival rate of the three lung cancer cells is obviously lower than that of a normal lung cancer cell group. Therefore, the application provides a new exploration for improving the sensitivity of radiotherapy, contributes to radiotherapy sensitivity of malignant tumor and has certain clinical application prospects.

A method of image-guided radiotherapy for treatment of a radio-resistant or radio-sensitive tumor. A three-dimensional visualized tumor image is obtained and the boundary of the tumor is identified. A boosted radiation dose of treatment is designated and applied to a boost region within the tumor boundary. A predetermined prescribed radiation dose is simultaneously applied with the boosted radiation dose within the tumor boundary and in a planning target volume region, which is outside of the tumor boundary. The boosted radiation dose outside of the boost region decreases at a boost dose decreasing rate such that the boosted radiation dose is equal to the predetermined prescribed radiation dose at the tumor boundary.